Faris Farassati, PhD, PharmD,

Faris Farassati, PhD, PharmD,

University of Kansas

H-index: 19

North America-United States

About Faris Farassati, PhD, PharmD,

Faris Farassati, PhD, PharmD,, With an exceptional h-index of 19 and a recent h-index of 13 (since 2020), a distinguished researcher at University of Kansas, specializes in the field of Cancer Research, Gene Therapy, Molecular Oncology, Oncolytic Viruses.

His recent articles reflect a diverse array of research interests and contributions to the field:

Identifying the main barriers for participation in a population-based colorectal cancer screening programme in East Azerbaijan, Iran

Cross-cultural validation of stool Based Colorectal cancer screening methods in the North West of Iran

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer

Development and Validation of Persian Risk Assessment Tool using National Comprehensive Cancer Network Guideline for Colorectal Cancer Screening.

The APC gene rs41115 polymorphism is associated with survival in Iranian colorectal cancer patients

Targeting cancer stem cells by oncolytic viruses and nano-mediated delivery

Value of Enhancer of Zeste Homolog 2 (EZH2) for Determining Prognosis in Colon Cancer.

Faris Farassati, PhD, PharmD, Information

University

Position

The University of Kansas Medical Center

Citations(all)

1445

Citations(since 2020)

562

Cited By

1131

hIndex(all)

19

hIndex(since 2020)

13

i10Index(all)

29

i10Index(since 2020)

16

Email

University Profile Page

Google Scholar

Faris Farassati, PhD, PharmD, Skills & Research Interests

Cancer Research

Gene Therapy

Molecular Oncology

Oncolytic Viruses

Top articles of Faris Farassati, PhD, PharmD,

Title

Journal

Author(s)

Publication Date

Identifying the main barriers for participation in a population-based colorectal cancer screening programme in East Azerbaijan, Iran

ecancermedicalscience

Roya Dolatkhah

Mohammad Hossein Somi

Saeed Dastgiri

Mohammad Asghari Jafarabadi

Bita Sepehri

...

2022

Cross-cultural validation of stool Based Colorectal cancer screening methods in the North West of Iran

Annals of Medicine and Surgery

Roya Dolatkhah

Mohammad Hossein Somi

Saeed Dastgiri

Mohammad Asghari Jafarabadi

Hossein Mashhadi Abdolahi

...

2022/4/1

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer

BioImpacts: BI

Roya Dolatkhah

Saeed Dastgiri

Amir Taher Eftekhar Sadat

Faris Farassati

Marzieh Nezamdoust

...

2021

Development and Validation of Persian Risk Assessment Tool using National Comprehensive Cancer Network Guideline for Colorectal Cancer Screening.

Journal of Clinical & Diagnostic Research

ROYA DOLATKHAH

SAEED DASTGIRI

MOHAMMAD ASGHARI JAFARABADI

HOSSEIN ABDOLAHI

BITA SEPEHRI

...

2020/1/1

The APC gene rs41115 polymorphism is associated with survival in Iranian colorectal cancer patients

Biomedical Research and Therapy

Sousan Mir Najd Gerami

Mohammad Hossein Somi

Leila Vahedi

Faris Farassati

Roya Dolatkhah

2020/9/30

Targeting cancer stem cells by oncolytic viruses and nano-mediated delivery

Mahsa Hosseini

Fatemeh S Farassati

Faris Farassati

2020/9/22

Value of Enhancer of Zeste Homolog 2 (EZH2) for Determining Prognosis in Colon Cancer.

Journal of Clinical & Diagnostic Research

NASSRIN GHOLAMI

ZOHREH SANAAT

ROYA DOLATKHAH

ALIREZA NIKANFAR

ALI ESFAHANI

...

2020/3/1

See List of Professors in Faris Farassati, PhD, PharmD, University(University of Kansas)